342 related articles for article (PubMed ID: 33545801)
1. Immune checkpoint inhibitor-induced myocarditis in lung cancer patients: a case report of sintilimab-induced myocarditis and a review of the literature.
Bi H; Ren D; Wang Q; Ding X; Wang H
Ann Palliat Med; 2021 Jan; 10(1):793-802. PubMed ID: 33545801
[TBL] [Abstract][Full Text] [Related]
2. Myocarditis related to immune checkpoint inhibitors treatment: two case reports and literature review.
Chen Y; Jia Y; Liu Q; Shen Y; Zhu H; Dong X; Huang J; Lu J; Yin Q
Ann Palliat Med; 2021 Jul; 10(7):8512-8517. PubMed ID: 34263614
[TBL] [Abstract][Full Text] [Related]
3. A case of subclinical immune checkpoint inhibitor-associated myocarditis in non-small cell lung cancer.
Hu Y; Liu C; Jin S; Yi Z; Wang C; Pan X; Huang H
BMC Pulm Med; 2023 Apr; 23(1):119. PubMed ID: 37060029
[TBL] [Abstract][Full Text] [Related]
4. Case Report: Glucocorticoid Effect Observation in a Ureteral Urothelial Cancer Patient With ICI-Associated Myocarditis and Multiple Organ Injuries.
Hu X; Wei Y; Shuai X
Front Immunol; 2021; 12():799077. PubMed ID: 34975911
[TBL] [Abstract][Full Text] [Related]
5. Isolated adrenocorticotropic hormone deficiency associated with sintilimab therapy in a patient with advanced lung adenocarcinoma: a case report and literature review.
Lin SH; Zhang A; Li LZ; Zhao LC; Wu LX; Fang CT
BMC Endocr Disord; 2022 Sep; 22(1):239. PubMed ID: 36153581
[TBL] [Abstract][Full Text] [Related]
6. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
7. Anlotinib succeeded in rescue therapy for hyperprogression induced by immune checkpoint inhibitors: a case report.
Chen L; Liu D; Zhang Y; Jia Y; Zhao X; Liu M; Kong T
Immunotherapy; 2023 Jun; 15(9):631-639. PubMed ID: 37020412
[TBL] [Abstract][Full Text] [Related]
8. A retrospective study of immune checkpoint inhibitor-associated myocarditis in a single center in China.
Wang F; Sun X; Qin S; Hua H; Liu X; Yang L; Yang M
Chin Clin Oncol; 2020 Apr; 9(2):16. PubMed ID: 32279526
[TBL] [Abstract][Full Text] [Related]
9. Toxic epidermal necrolysis induced by sintilimab in a patient with advanced non-small cell lung cancer and comorbid pulmonary tuberculosis: A case report.
Li G; Gong S; Wang N; Yao X
Front Immunol; 2022; 13():989966. PubMed ID: 36090976
[TBL] [Abstract][Full Text] [Related]
10. [Clinical and histopathological features of immune checkpoint inhibitor-related myositis in patients with advanced non-small cell lung cancer].
Jiang JJ; Li YQ; Gu YY
Zhonghua Jie He He Hu Xi Za Zhi; 2022 Jan; 45(1):47-52. PubMed ID: 35000305
[No Abstract] [Full Text] [Related]
11. Upper Gastrointestinal Tract IrAEs: A Case Report About Sintilimab-Induced Acute Erosive Hemorrhagic Gastritis.
Ai Q; Chen W; Li Y; Li G
Front Immunol; 2022; 13():840916. PubMed ID: 35720298
[TBL] [Abstract][Full Text] [Related]
12. A Fatal Case of Myocarditis Following Myositis Induced by Pembrolizumab Treatment for Metastatic Upper Urinary Tract Urothelial Carcinoma.
Matsui H; Kawai T; Sato Y; Ishida J; Kadowaki H; Akiyama Y; Yamada Y; Nakamura M; Yamada D; Akazawa H; Suzuki M; Komuro I; Kume H
Int Heart J; 2020 Sep; 61(5):1070-1074. PubMed ID: 32921673
[TBL] [Abstract][Full Text] [Related]
13. A case of acute myocarditis induced by PD-1 inhibitor (sintilimab) in the treatment of large cell neuroendocrine carcinoma.
Zheng S; Zhang H; Hu B; Zhou J; Wen L; Li M
Heliyon; 2023 Jun; 9(6):e16874. PubMed ID: 37342584
[TBL] [Abstract][Full Text] [Related]
14. Promising response to a PD-1 inhibitor (sintilimab) in non-small cell lung cancer: A case report.
Zhang L; Mai W; Hao B; Jiang W; Geng Q
Medicine (Baltimore); 2020 May; 99(21):e19790. PubMed ID: 32481252
[TBL] [Abstract][Full Text] [Related]
15. Severe immune-related hyperthermia followed by immune-related pneumonitis with PD-1 inhibitor (sintilimab) in small cell lung cancer: A case report.
Li YH; Zhou Y; Liu YY; Zhang GJ; Xiao L; Li N; Qin HF; Wang JG; Zhang L
Thorac Cancer; 2021 Jun; 12(11):1780-1783. PubMed ID: 33949137
[TBL] [Abstract][Full Text] [Related]
16. A case report and literature review on respiratory failure with immune checkpoint inhibitors: a life-threatening adverse event.
Lin X; Guan W; Li B; Deng H; Chen Y; Yang Y; Qiu G; Xie X; Zhou C
Immunopharmacol Immunotoxicol; 2023 Dec; 45(6):780-787. PubMed ID: 37339370
[TBL] [Abstract][Full Text] [Related]
17. Hyper-progressive disease in a patient with advanced non-small cell lung cancer on immune checkpoint inhibitor therapy: A case report and literature review.
Zhang D; Zhang Y; Huang Y; Kong L; Yu J
Lung Cancer; 2020 Jan; 139():18-21. PubMed ID: 31704279
[TBL] [Abstract][Full Text] [Related]
18. Sintilimab-Induced Myocarditis in a Patient with Gastric Cancer: A Case Report and Literature Review.
Liu X; Zeng Z; Cao J; Li X; Muhetaer M; Jin Z; Cai H; Lu Z
J Cardiovasc Dev Dis; 2023 Oct; 10(10):. PubMed ID: 37887869
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint inhibitor sintilimab-induced lethal myocarditis overlapping with myasthenia gravis in thymoma patient: A case report.
Wang C; Zhong B; He J; Liao X
Medicine (Baltimore); 2023 Apr; 102(15):e33550. PubMed ID: 37058040
[TBL] [Abstract][Full Text] [Related]
20. Re-introducing immunotherapy in patients surviving immune checkpoint inhibitors-mediated myocarditis.
Peleg Hasson S; Salwen B; Sivan A; Shamai S; Geva R; Merimsky O; Raphael A; Shmilovich H; Moshkovits Y; Kapusta L; Rozenbaum Z; Wolf I; Laufer-Perl M
Clin Res Cardiol; 2021 Jan; 110(1):50-60. PubMed ID: 32296970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]